Clinical Trial Planner tool provides subjects/sites/investigators availability by Drug Indication, Phase and Nature of Molecule, and Enrollment Size.
Drugs coverage include under development and approved therapies. Drug profile covers exhaustive research, regulatory and market information from global pharm/biotech companies and regulatory websites. Regulatory designations from United States, Europe, Japan, South Korea, Australia, China and United Kingdom regulatory websites. Drug sales and forecast estimates for the major countries. Complex technologies are linked to drugs, companies and deals.
Clinical trials, trial sites, investigators and contacts from prominent clinical trial registries. Lot of unstructured data parsed, curated and connected with relevant sponsors, collaborators, interventions, indications, sites and investigators. Conditions are standardized accordingly to match with other data modules.
Companies, Institutes, Universities and Tech Transfer entities associated with technologies, drugs, contract manufacturing, and clinical research services, and pharma or biotech portfolio investment interest are covered. Platform provides search filters, data exports and alerts on company attributes, financials along with Global Industry Classification System (GICS) and disruptive technologies. Dynamic news, deals coverage and key people contacts by department.
Contract services database covers manufacturing, clinical trials and packaging companies with their capabilities. Covers drugs, contacts, news, agreements, certifications and warnings issued by manufacturing facility and clinical site.
Covers generic drugs from developed and developing market countries with their reference drugs. Sales & marketing and market strategy teams can make most use of the data as it gives broader view on generic market by country. Active Drug Master Files (DMF) data by generic name and company from United States, EU, Japan and South Korea combined with generic approval data. Companies with only DMF approvals are the right target companies to make service agreements for generic companies.
Instant data view on global pipeline and approved drugs, associated companies, clinical trials, trial sites, investigators, drug price, drug sales and regulatory information for the required data set. Data visualization and analytics based on the content helps you with ready-to-use exports and analytics. Dynamic updates and new additions as per your subscribed content saves time and money.
Database covers major unmet need and rare indications by incidence, prevalence, disease characteristics, and market size for more than 40+ countries. Customized insights on current treatments, promising pipeline drugs, active companies/institutes/universities and active trial sponsors/collaborators. Strategic data representation with drug sales and forecast, patent landscape, review designations, strategic deals and licensing opportunity data.
Company competitive intelligence tool provides similar companies by Headquarters, Disease Area, Nature of Molecule, Pipeline/Approved stages and Business Type. Provides ready-to-use templates by company with basic details, financials, key people, drug sales and performance Metrix. Clinical Trial Planner tool provides subjects/sites/investigators availability by Drug Indication, Phase and Nature of Molecule, and Enrollment Size.
Doloxe offers centralized data repository that caters data intelligence, trends and insights as a service to help organization make informed decisions.
Our data experts and softwares curate all your requirments into actionable insights.
Curate data from company websites, press newswires, financial statements and reports. Each deliverable include data specific source types for your reference.
Single platform for pharmaceutical industry data research, market and projections.
Consulting services based on your goals and return on investment (ROI) optimised strategies on any selected industry trend and disease landscape report.
Data analytics from multiple platforms helps you ready-to-use presentation templates for the strategy meetings and key analysis.
Know and inspect new and enhancements from our competitors and add value-driven offerings to support you with integrated platform approach.
Doloxe foresee customer success through their products and services along with other biopharma players. We get into the customer strategy, align with their offerings and come up with better solutions. Our technologies ensure data solutions are comprehensive and making an insightful offering. Each insight derives from the depth and breadth of the drug development cycle, includes technology, drug phase, molecule structure, route of administration, disease analysis, multiple entities such as originator, licensor, licensee, technology partner, CRO, CDMO/CMO, clinical trial location, investigator, pivotal trial, patents, future events, drug price and reimbursement.
Customer service is our opportunity to fill gap within the biopharmaceutical industry supply chain. We strive to create value addition to each industry player requirements and make more customer success stories.
Our leadership, scientific and technology team strives for continuous improvements in terms of client friendly data technologies, latest scientific innovations and access to the right analyst.
Query management team ensures with relevant reply within promised turnaround time.
Our support staff will respond to your customized requirements and queries as soon as possible.
Our customer success team work alongside with your account manager to support you on all modules and intelligence platforms. Our objective is to make use of our modules and benefit with informed decisions.
We have 24/5 support across all regions, please shoot us an email if you have access issues or have any urgent requirements
We keep you informed, profound and favorable decisions to encompass the advantages of upcoming trends, progressions, estimations, and opportunities through our precise understanding of the market.
TECVAYLI™, an off-the-shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options
HORSHAM, Pa., Oct. 25, 2022 /PRNews...
RegeneRx Biopharmaceuticals, Inc. reported that its U.S. joint venture (JV) partner and licensee, HLB Therapeutics (HLBT), has announced that it submitted a request for the Special Protocol Assessment...Read more..
WuXi Biologics adds further capacity and capability for drug product fill & finish, providing global customers with end-to-end integrated solutions for diversified modalities, including mRNA-LNP
HUYABIO International (HUYABIO™), the leader in accelerating global development of China's pharmaceutical innovations, today announced the submission of a regulatory application to the Japanese Pharma...Read more..
- Trial demonstrates cumulative incidence of death or respiratory failure through day 28 was 18.1% (26 of 144) with tofacitinib compared to 29.0% (42 of 145) with placebo, in hospitalized patients wit...Read more..